

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT6428722

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	SUPPLEMENT TO CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS
CONVEYING PARTY DATA	
Name	Execution Date
BIOSPECIFICS TECHNOLOGIES CORP.	12/02/2020
RECEIVING PARTY DATA	
Name:	WILMINGTON TRUST, NATIONAL ASSOCIATION
Street Address:	1100 NORTH MARKET STREET
City:	WILMINGTON
State/Country:	DELAWARE
Postal Code:	19890
PROPERTY NUMBERS Total: 14	
Property Type	Number
Patent Number:	10119131
Application Number:	16180156
Application Number:	17004857
Patent Number:	9744138
Patent Number:	10369110
Application Number:	15666365
Application Number:	16506435
Application Number:	14853245
Patent Number:	10272140
Application Number:	62915360
Application Number:	62915363
Application Number:	62915367
Application Number:	17070747
Application Number:	63092290
CORRESPONDENCE DATA	
Fax Number:	(212)455-2502
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	(212)455-2055
Email:	ksolomon@stblaw.com

PATENT

Correspondent Name:	KATE MIRINO, ESQ.
Address Line 1:	SIMPSON THACHER & BARTLETT LLP
Address Line 2:	425 LEXINGTON AVENUE
Address Line 4:	NEW YORK, NEW YORK 10017

ATTORNEY DOCKET NUMBER:	509265-2182
--------------------------------	-------------

NAME OF SUBMITTER:	KATE MIRINO
---------------------------	-------------

SIGNATURE:	/KM/
-------------------	------

DATE SIGNED:	12/02/2020
---------------------	------------

Total Attachments: 6

source=Endo (BioSpecifics) - 1L Patent Short Form Supplement (Executed)#page1.tif

source=Endo (BioSpecifics) - 1L Patent Short Form Supplement (Executed)#page2.tif

source=Endo (BioSpecifics) - 1L Patent Short Form Supplement (Executed)#page3.tif

source=Endo (BioSpecifics) - 1L Patent Short Form Supplement (Executed)#page4.tif

source=Endo (BioSpecifics) - 1L Patent Short Form Supplement (Executed)#page5.tif

source=Endo (BioSpecifics) - 1L Patent Short Form Supplement (Executed)#page6.tif

**SUPPLEMENT TO CONFIRMATORY GRANT OF SECURITY INTEREST
IN UNITED STATES PATENTS**

THIS SUPPLEMENT TO CONFIRMATORY GRANT OF SECURITY INTEREST IN UNITED STATES PATENTS (as the same may be amended, restated, supplemented or otherwise modified from time to time, the "Confirmatory Grant") is made effective as of December 2, 2020 by and from BIOSPECIFICS TECHNOLOGIES CORP. (the "Grantor"), to and in favor of WILMINGTON TRUST, NATIONAL ASSOCIATION, for itself and as Collateral Trustee (as defined in the Collateral Trust Agreement referenced below) for the Secured Parties (as defined in the Collateral Trust Agreement referenced below) (in such capacities, the "Grantee").

WHEREAS, reference is made to (a) that certain Credit Agreement, dated as of April 27, 2017 (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Credit Agreement"), by and among ENDO INTERNATIONAL PLC, a company organized under the laws of Ireland (Registered Number 534814) ("Parent"), Endo Luxembourg Finance Company I S.à r.l., a société à responsabilité limitée (private limited liability company) incorporated under the laws of the Grand Duchy of Luxembourg, having its registered office at 2a, rue Nicolas Bové, L-1253 Luxembourg and registered with the Luxembourg Register of Commerce and Companies under number B182645 (the "Lux Borrower"), Endo LLC, a Delaware limited liability company (the "Co-Borrower" and, together with the Lux Borrower, the "Borrowers"), the lenders from time to time party thereto and JPMORGAN CHASE BANK, N.A., as administrative agent (in such capacity, together with its successor and permitted assigns, the "Credit Agreement Agent"), (b) that certain Indenture, dated as of April 27, 2017 (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "2024 Indenture"), by and among Endo Designated Activity Company, a company organized under the laws of Ireland (Registered Number 534651) ("EDAC"), Endo Finance LLC, a Delaware limited liability company ("Finance LLC") and Endo Finco Inc., a Delaware corporation (together with EDAC and Finance LLC, collectively, the "2024 Issuers"), certain affiliates of the 2024 Issuers from time to time party thereto as guarantors, and Wells Fargo Bank, National Association, as trustee (in such capacity, together with its successors and permitted assigns in such capacity, the "Indenture Trustee"), (c) that certain Indenture, dated as of March 28, 2019 (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "2027 Indenture") by and among Par Pharmaceutical, Inc. (the "2027 Issuer" and, together with the 2024 Issuers, the "Issuers"), certain affiliates of the 2027 Issuer from time to time party thereto as guarantors, and the Indenture Trustee, as trustee and (d) that certain Collateral Trust Agreement, dated as of April 27, 2017 (as the same may be amended, restated, amended and restated, supplemented or otherwise modified from time to time, the "Collateral Trust Agreement"), by and among Parent, the Borrowers, the Issuers, the other grantors from time to time party thereto and Wilmington Trust, National Association, in its capacity as Collateral Trustee (the "Collateral Trustee") for the Secured Parties (as defined in the Collateral Trust Agreement), the Credit Agreement Agent, the Indenture Trustee and the other parties from time to time party thereto;

WHEREAS, the Grantors and certain Domestic Subsidiaries of Parent have entered into a US Pledge and Security Agreement dated as of April 27, 2017 (as may be amended, restated, supplemented or otherwise modified from time to time, the "US Security Agreement");

WHEREAS, the Grantors own the patents and patent applications listed on Schedule A attached hereto (the "Patents"), which Patents have been issued by or are pending applications in the United States Patent and Trademark Office; and

WHEREAS, this Confirmatory Grant has been executed in conjunction with the security interest granted under the US Security Agreement to the Grantee for the benefit of the Secured Parties. In the event that any provisions of this Confirmatory Grant are deemed to conflict with the US Security Agreement, the provisions of the US Security Agreement shall govern.

NOW, THEREFORE, in consideration of the mutual covenants and agreements set forth herein and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, it is hereby agreed that:

1. Definitions. All capitalized terms not defined herein shall have the respective meaning given to them in the US Security Agreement.

2. The Security Interest.

(a) This Confirmatory Grant is made to secure the prompt and complete performance and payment of all the Secured Obligations. Upon the occurrence of the Termination Date (as defined in the US Security Agreement), the Grantee shall promptly, upon such satisfaction, execute, acknowledge, and deliver to the Grantors all reasonably requested instruments in writing releasing the security interest in the Patents acquired under the US Security Agreement and this Confirmatory Grant.

(b) The Grantors hereby pledge and grant to the Grantee, on behalf of and for the benefit of the Secured Parties, a security interest in all of the Grantors' right, title and interest, wherever located and whether now owned or hereafter acquired, in and to (1) any and all patents and patent applications, including the Patents; (2) all inventions and improvements described and claimed therein; (3) all reissues, divisionals, continuations, renewals, extensions, and continuations-in-part thereof; (4) all income, royalties, damages, claims, and payments now or hereafter due or payable under and with respect thereto, including, without limitation, damages and payments for past and future infringements thereof; (5) all rights to sue for past, present, and future infringements thereof; and (6) all rights corresponding to any of the foregoing throughout the world.


3. Governing Law. **THIS CONFIRMATORY GRANT SHALL BE CONSTRUED IN ACCORDANCE WITH AND GOVERNED BY THE LAW OF THE STATE OF NEW YORK.**

4. Notwithstanding anything to the contrary set forth herein, the priority of the Liens created hereby and the rights and remedies of the Collateral Trustee hereunder are subject to the terms and provisions of the Collateral Trust Agreement and the US Security Agreement. In the event of any inconsistency between the provisions of this Confirmatory Grant and the Collateral

Trust Agreement or the US Security Agreement with respect to the priority of the Liens created hereby and the rights and remedies of the Collateral Trustee, the provisions of the Collateral Trust Agreement and/or the US Security Agreement shall supersede the provisions of this Confirmatory Grant. Any provision of this Confirmatory Grant to the contrary notwithstanding, the Grantors shall not be required to act or refrain from acting in a manner that is inconsistent with the terms and provisions of the Collateral Trust Agreement or the US Security Agreement.

IN WITNESS WHEREOF, the Grantor has executed this Confirmatory Grant effective as of the date first written above.


BIOSPECIFICS TECHNOLOGIES CORP.,
as Grantor

By: _____

Name: Deanna Voss

Title: Assistant Secretary

WILMINGTON TRUST, NATIONAL
ASSOCIATION,
as Collateral Trustee and Grantee

By _____
Name: Andrew Lennon
Title: Assistant Vice President

Schedule A

Patents

<u>COUNTRY</u>	<u>TITLE</u>	<u>REG. (APP.) NO.</u>	<u>REG. (APP.) DATE</u>	<u>OWNERSHIP</u>
US	Compositions and methods for producing clostridial collagenases	10,119,131	11/6/2018	BioSpecifics Technologies Corp.
US	Compositions and methods for producing clostridial collagenases	(16/180,156)	11/5/2018	BioSpecifics Technologies Corp.
US	Compositions and methods for producing clostridial collagenases	(17/004,857)	8/27/2020	BioSpecifics Technologies Corp.
US	Treating method and product for uterine fibroids using purified collagenase	9,744,138	8/29/2017	Co-owned by BioSpecifics Technologies Corp., Duke University and North Carolina Central University
US	Treating method and product for uterine fibroids using purified collagenase	10,369,110	8/6/2019	Co-owned by BioSpecifics Technologies Corp. and Duke University
US	Treating method and product for uterine fibroids using purified collagenase	(15/666,365)	(8/1/2017)	Co-owned by BioSpecifics Technologies Corp. and Duke University
US	Treating method and product for uterine fibroids using purified collagenase	(16/506,435)	(7/9/2019)	Co-owned by BioSpecifics Technologies Corp. and Duke University
US	Treating method and product for uterine fibroids using purified collagenase	(17/769,197)	(10/6/2020)	Co-owned by BioSpecifics Technologies Corp. and Duke University
US	Thermosensitive Hydrogel Collagen use Formulations	(14/853,245)	(9/14/2016)	BioSpecifics Technologies Corp.
US	Thermosensitive Hydrogel Collagenase Formulations	10,272,140	4/30/2019	BioSpecifics Technologies Corp.
US	Treatment of Uterine Fibroids using Purified Collagenase	(62/915,360)	10/15/2019	BioSpecifics Technologies Corp., The Johns Hopkins University and Duke University
US	Treatment of Uterine Fibroids using Purified Collagenase	(62/915,363)	10/15/2019	BioSpecifics Technologies Corp., The Johns Hopkins University and Duke University
US	Treatment of Uterine Fibroids using Purified Collagenase	(62/915,367)	10/15/2019	BioSpecifics Technologies Corp., The Johns Hopkins University and Duke University
US	Treatment of Uterine Fibroids using Purified Collagenase	(17/070,747)	10/14/2020	BioSpecifics Technologies Corp., The Johns Hopkins University and Duke University
US	Thermosensitive Hydrogel Collagenase Formulations	(63/092,290)	10/15/2020	BioSpecifics Technologies Corp., North Carolina State University and Duke University

PATENT

RECORDED: 12/02/2020

REEL: 054575 FRAME: 0685